Cargando…
A Short-Term Biological Indicator for Long-Term Kidney Damage after Radionuclide Therapy in Mice
Folate receptor (FR)-targeted radionuclide therapy using folate radioconjugates is of interest due to the expression of the FR in a variety of tumor types. The high renal accumulation of radiofolates presents, however, a risk of radionephropathy. A potential option to address this challenge would be...
Autores principales: | Pellegrini, Giovanni, Siwowska, Klaudia, Haller, Stephanie, Antoine, Daniel J., Schibli, Roger, Kipar, Anja, Müller, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5490414/ https://www.ncbi.nlm.nih.gov/pubmed/28635637 http://dx.doi.org/10.3390/ph10020057 |
Ejemplares similares
-
Folate Receptor-Positive Gynecological Cancer Cells: In Vitro and In Vivo Characterization
por: Siwowska, Klaudia, et al.
Publicado: (2017) -
Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate
por: Haller, Stephanie, et al.
Publicado: (2016) -
Prospects in Folate Receptor-Targeted Radionuclide Therapy
por: Müller, Cristina, et al.
Publicado: (2013) -
Combining Albumin-Binding Properties and Interaction with Pemetrexed to Improve the Tissue Distribution of Radiofolates
por: Müller, Cristina, et al.
Publicado: (2018) -
Promising potential of [(177)Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model
por: Guzik, Patrycja, et al.
Publicado: (2020)